Boehringer’s Jardiance receives approval for chronic kidney disease treatment in India 

INDIA – Boehringer Ingelheim’s Jardiance has received approval from the Central Drugs Standard Control Organisation of India for the treatment of chronic kidney disease (CKD), marking a significant milestone in addressing the needs of patients grappling with this condition. 

 The approval now allows nephrologists and cardiologists to utilize Jardiance 10mg tablets in eligible CKD patients, potentially transforming the standard of care for millions of individuals across the country. 

Clinical trials have demonstrated Jardiance’s efficacy in reducing the risk of various complications associated with CKD, including sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization. 

 eGFR, a vital indicator of kidney function, serves as a crucial metric in assessing the progression of CKD. 

With an estimated 33 million adults in India affected by CKD, this approval holds the promise of alleviating the burden on healthcare systems by mitigating the risk of hospitalizations and slowing down the progression to kidney failure.  

This development is particularly significant given the pressing need for therapies that can effectively slow down the advancement of CKD and improve patient outcomes. 

Gagandeep Singh Bedi, MD of Boehringer Ingelheim India, emphasized the importance of addressing the unmet medical needs in CKD treatment. 

 He expressed excitement regarding the approval of empagliflozin and its potential to significantly impact the lives of individuals battling kidney disease.